Carmen Molica
University of Perugia
5 Papers
25 Citations
Carmen Molica is an academic researcher from University of Perugia. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Telomerase reverse transcriptase. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.
Giulio Metro,Sara Baglivo,Guido Bellezza,Martina Mandarano,Alessio Gili,Giovanni Marchetti,Marco Toraldo,Carmen Molica,Maria Sole Reda,Francesca Romana Tofanetti,Annamaria Siggillino,Enrico Prosperi,Antonella Giglietti,Bruna Di Girolamo,Miriam Garaffa,Francesca Marasciulo,Vincenzo Minotti,Marco Gunnellini,Annalisa Guida,Monica Sassi,Angelo Sidoni,Fausto Roila,Vienna Ludovini +22 more
TL;DR: In this article, the clinical outcome of patients with this EGFR mutation subtype in the immunotherapy era was determined, and a trend towards an inferior outcome in terms of PFS and overall survival was observed for patients receiving ICB treatment in the first versus second line setting (PFS: 1.6 months versus 2.7 months, respectively).
37
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma
Tiziana Pierini,Carlotta Nardelli,Anair Graciela Lema Fernandez,Valentina Pierini,Fabrizia Pellanera,Valeria Nofrini,Paolo Gorello,Martina Moretti,Silvia Arniani,Giovanni Roti,Paolo Giovenali,Marco Lupattelli,Giulio Metro,Carmen Molica,Corrado Castrioto,Rodolfo Corinaldesi,Maria Elena Laurenti,Stefano Ascani,Cristina Mecucci,Roberta La Starza +19 more
TL;DR: New insights are provided into TERTp mutational spectrum occurring in central nervous system tumors, with the identification of new recurrent somatic gain-of-function mutations, occurring in 0.8% of glioblastoma IDH-wildtype.
A novel germline mutation in CDK4 codon 24 associated to familial melanoma.
Irene Bottillo,R La Starza,Francesca Clementina Radio,Carmen Molica,Lucia Pedace,Tiziana Pierini,C. De Bernardo,Luca Stingeni,Simone Bargiacchi,Alessandro Paiardini,Giacomo Janson,Christina Mecucci,Paola Grammatico +12 more
TL;DR: Predicting Gibbs free energy of binding variations (ΔΔG, in kcal/mol) between CDK4 and its partners upon mutations and values indicate decrease affinity are shown.
5
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts).
Giulio Metro,Simona Duranti,Rita Chiari,Chiara Bennati,Carmen Molica,Maria Francesca Currà,Chiara Scafati,Annamaria Siggillino,A. Flacco,Luca Marcomigni,Vienna Ludovini,Vincenzo Minotti,Lucio Crinò +12 more
TL;DR: This data indicates that treatment with a reversible EGFR-TKI may benefit pts with EGFR WT advanced NSCLC, though to a much lesser extent than pts carrying an activating mutation in the EGFR gene.
2
Prevalence and Spectrum of BRCA Germline Variants in Central Italian High Risk or Familial Breast/Ovarian Cancer Patients: A Monocentric Study.
Jennifer Foglietta,Vienna Ludovini,Fortunato Bianconi,Lorenza Pistola,Maria Sole Reda,Antonella Al-Refaie,Francesca Romana Tofanetti,Annamaria Mosconi,Elisa Minenza,P. Anastasi,Carmen Molica,Fabrizio Stracci,Fausto Roila +12 more
TL;DR: The study reveals that the overall frequency of BRCA germline variants in the selected high-risk Italian population is about 13.8%, which could have significant implications for preventive strategies for unaffected BRCa-carriers and effective targeted treatments for patients with BC or OC.